戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ne and again in the presence of serotonin or oxotremorine.
2  of dystonia-like movement alterations after oxotremorine.
3 arinic receptor-activated Kir3 currents with oxotremorine.
4 triatal injection of the cholinergic agonist oxotremorine.
5 nge with the nonselective muscarinic agonist oxotremorine.
6 The nonsubtype-selective muscarinic agonist, oxotremorine (0.1-10 microm), inhibited potassium-stimul
7 s mimicked by a muscarinic receptor agonist (oxotremorine; 1 mum), and blunted by M1- (pirezenpine; 2
8 infusions of the muscarinic receptor agonist oxotremorine (10 ng/0.2 microliter per side) or saline.
9                                              Oxotremorine (a muscarinic agonist) and (-)butylthio[2.2
10 elated to the cerebral hyperemic response to oxotremorine, a muscarinic agonist that increases cerebr
11 /m4) receptor antagonists resulted in robust oxotremorine-activated Kir3 currents.
12 uscarinic agonist (arecoline, pilocarpine or oxotremorine), an acetylcholinesterase inhibitor (tacrin
13                                              Oxotremorine, an m2 muscarinic acetylcholine receptor (m
14                 Prior to behavioral testing, oxotremorine, an M2 muscarinic receptor agonist that red
15             After systemic administration of oxotremorine, an unselective cholinergic agonist, Gnal(+
16             The standard muscarinic agonists oxotremorine and pilocarpine were both active in these t
17 ter, the effects of intraseptal scopolamine, oxotremorine, and muscimol were tested in a T-maze alter
18 mpletely blocked AMPH-stimulated SP mRNA and oxotremorine at 8.1 mM blocked AMPH-stimulated PPD mRNA.
19 mine into the dorsal striatum augmented, and oxotremorine attenuated, AMPH (2.5 mg/kg, i.p.)-stimulat
20 ts, whereas the muscarinic receptor agonist, oxotremorine, attenuates behaviors (locomotion and stere
21 ntrast, systemic scopolamine blocks, whereas oxotremorine augments, AMPH-stimulated preproenkephalin
22              However, both concentrations of oxotremorine completely blocked AMPH-stimulated SP mRNA
23  activation of M2 receptors in the pIC using oxotremorine completely reversed oxaliplatin-induced mec
24                           Both serotonin and oxotremorine depolarize and excite isolated individual G
25      Intrastriatal infusion of 1.6 or 8.1 mM oxotremorine did not alter basal levels of striatal PPD
26 ese effects by administering scopolamine and oxotremorine directly into the striatum and assessing th
27                                Serotonin and oxotremorine each increased the size of the parameter re
28  the following parameters were examined: (1) oxotremorine-enhanced striatal dopamine release (OX-K+-E
29 euronal and behavioral parameters including: oxotremorine enhancement of K(+)-evoked release of dopam
30 or, is potent (IC50 = 0.45 nM) in inhibiting oxotremorine-evoked [(3)H]DA release from rat striatal s
31 ppocampal infusions of a 1 microgram dose of oxotremorine exhibited significant deficits in freezing
32                                 Importantly, oxotremorine had no significant effects on ultrasound em
33 l muscarinic agonists, such as muscarine and oxotremorine, had higher affinity versus oxotremorine-M
34                                              Oxotremorine impaired accuracy similarly in control and
35                             Thus, effects of oxotremorine in the hippocampal dentate gyrus do not pro
36                                        These oxotremorine-induced abnormalities in Gnal(+/-) mice wer
37 ceptors in brains from GRK5-KO mice resisted oxotremorine-induced desensitization, as assessed by oxo
38 havioral deficits in freezing may reflect an oxotremorine-induced disruption of hippocampal cholinerg
39 , the BF-saporin rats were hypersensitive to oxotremorine-induced hypothermia and demonstrated an inc
40 alities in Gnal(+/-) mice were replicated by oxotremorine infusion into the striatum, but not into th
41                      Similarly, we find that oxotremorine inhibits rebound activity independently of
42 ion with the nonselective muscarinic agonist oxotremorine inhibits rebound activity more strongly in
43 the non-subtype-selective muscarinic agonist oxotremorine led to concentration-dependent increases in
44  with the largest cooperativity observed for oxotremorine M (Oxo-M) LY2119620.
45 ensitive to 100 microm Cd(2+) and 2.5 microm oxotremorine M (oxo-M), a muscarinic agonist, and fully
46 nergic agonist, and reduced 63% by 10 microM oxotremorine M (Oxo-M), a muscarinic agonist.
47                    Blockade of M currents by oxotremorine M or linopirdine prevented the depolarizing
48 acetylcholine receptors (i.e. application of oxotremorine M to PTX-treated neurons) failed to elicit
49               Using the mAChR agonist Oxo M (oxotremorine M), we identified a GAR-3(mAChR)-G alpha(q)
50                            The mAChR agonist oxotremorine-M (3-10 microM) dose-dependently decreased
51 efore compared the effects of bradykinin and oxotremorine-M (a muscarinic agonist) on membrane PIP(2)
52 ed with anti-CD3/CD28/CD2 in the presence of oxotremorine-M (M1R-M5R agonist), atropine (M1R-M5R anta
53 r hyperpolarized by the cholinergic agonists oxotremorine-M (Oxo-M) and carbachol (CCh), and that mAC
54 ave demonstrated that the muscarinic agonist oxotremorine-m (oxo-m) blocks the induction of presynapt
55 nts were modulated by the muscarinic agonist oxotremorine-M (oxo-M) in a manner having all of the cha
56 rinic acetylcholine receptor (mAChR) agonist oxotremorine-M (Oxo-M) in dissociated vestibular ganglio
57 bation of cells with the cholinergic agonist oxotremorine-M (Oxo-M) induced an approximately 6-fold i
58     Effects of a muscarinic receptor agonist oxotremorine-M (oxo-M) on bladder afferent nerve (BAN) a
59     Stimulation of M1 receptors by 10 microM oxotremorine-M (Oxo-M) strongly reduced (to 0-10%) curre
60  behavioral responsiveness to challenge with oxotremorine-M (Oxo-M), a nonselective muscarinic acetyl
61 oth were inhibited by 1 mM Ba2+ or 10 microM oxotremorine-M (Oxo-M).
62                                              Oxotremorine-M (OXO-M; 10 microM) produced a reversible
63                                 Furthermore, oxotremorine-M also dose-dependently increased the frequ
64                                              Oxotremorine-M also increased the sEPSC frequency in app
65 he magnitude of the full muscarinic agonists oxotremorine-M and cis-dioxolane.
66 eta-Acetoxynortropane had K(i) values versus oxotremorine-M binding at m(1)-, m(2)-, and m(4)-recepto
67 and oxotremorine, had higher affinity versus oxotremorine-M binding compared to quinuclidinyl benzila
68 loxy(nor)tropanes had higher affinity versus oxotremorine-M binding compared to quinuclidinyl benzila
69 ransfected m(3)-receptors, since significant oxotremorine-M binding could not be detected.
70  M4 subtype-preferring antagonist himbacine, oxotremorine-M caused a large increase in the sIPSC freq
71 prised to find that in M2/M4 double-KO mice, oxotremorine-M consistently increased the frequency of s
72     In wild-type mice, mAChR activation with oxotremorine-M decreased the amplitude of monosynaptic E
73               On the other hand, 1-10 microm oxotremorine-M dose-dependently increased the frequency
74                        In M5 single-KO mice, oxotremorine-M failed to potentiate evoked EPSCs, and it
75 I mGluRs eliminated the inhibitory effect of oxotremorine-M in M2/M4 double-KO mice.
76 4129 did not block the stimulatory effect of oxotremorine-M in the majority of neurons from WT mice.
77 e-M or potentiated the stimulatory effect of oxotremorine-M in WT mice.
78                                              Oxotremorine-M increased IFN-gamma and IL-17A while redu
79          Strikingly, in M(5)-single KO mice, oxotremorine-M increased sEPSCs in only 26.3% neurons, a
80                            The mAChR agonist oxotremorine-M increased the frequency of glutamatergic
81                     In M2/M4 double-KO mice, oxotremorine-M inhibited monosynaptic EPSCs in significa
82  mice, but not M(2)- or M(4)-single KO mice, oxotremorine-M inhibited sEPSCs in significantly fewer n
83 , the inhibitory and potentiating effects of oxotremorine-M on EPSCs in M3 single-KO and M1/M3 double
84 moting effect of Muscarinic receptor agonist oxotremorine-M on insulin secretion in cultured mouse is
85                  Surprisingly, the effect of oxotremorine-M on sIPSCs was largely attenuated at a hig
86 t 4-DAMP abolished the stimulatory effect of oxotremorine-M on sIPSCs.
87 P55845 potentiated the stimulatory effect of oxotremorine-M on sIPSCs.
88 similarly reduced the potentiating effect of oxotremorine-M on sIPSCs.
89 e either attenuated the inhibitory effect of oxotremorine-M or potentiated the stimulatory effect of
90                                              Oxotremorine-M pretreatment protected cells from H(2)O(2
91           In M3 KO and M1/M3 double-KO mice, oxotremorine-M produced a consistent decrease in the fre
92                  In M2 or M4 single-KO mice, oxotremorine-M produced a variable effect on sIPSCs; it
93                            The mAChR agonist oxotremorine-M significantly increased the frequency of
94 inositol metabolism, but mutant A212E caused oxotremorine-M to become a weak partial agonist compared
95 y blocked the binding of [(3)H]NMS and [(3)H]oxotremorine-M to M2 receptors with Hill coefficients ne
96 ial Bax accumulation, also was attenuated by oxotremorine-M treatment after treatment with H(2)O(2) o
97                     The inhibitory effect of oxotremorine-M was attenuated by the M2/M4 antagonist hi
98 st (quinuclidinyl benzilate) and an agonist (oxotremorine-M) at sites on human m(1)-, m(2)-, m(3)-, a
99     At low concentrations (e.g. 0.1-1 microM oxotremorine-M), 'burst-mode' activity comprised regular
100 ressive decrease in the apparent affinity of oxotremorine-M).
101                            Pretreatment with oxotremorine-M, a selective agonist of muscarinic recept
102 arter of the reduction in PIP(2) produced by oxotremorine-M, but equal reduction when PIP(2) synthesi
103 ent with the nonselective muscarinic agonist oxotremorine-M, M2, and M4 receptors underwent significa
104 c receptors were stimulated with the agonist oxotremorine-M, several previously described currents we
105 gonists, acetylcholine (ACh), carbachol, and oxotremorine-M, while significantly increasing the maxim
106                                              Oxotremorine-M-induced activation of AP-1 was 40--53% lo
107       Blocking or knocking out M3R prevented oxotremorine-M-induced increases in IFN-gamma and IL-17A
108  blocked the nonselective muscarinic agonist oxotremorine-M-induced increases in neuronal firing rate
109 y decreased the promoting effect of SPARC on oxotremorine-M-stimulated insulin secretion.
110  in combination with the M2 receptor agonist oxotremorine-M.
111 gnificantly reduced the inhibitory effect of oxotremorine-M.
112  of N-[(3)H]methylscopolamine by the agonist oxotremorine-M.
113 entiation of AMPK phosphorylation induced by oxotremorine-M.
114 nhibitor dephostatin prevented inhibition by oxotremorine-M.
115                                  Strikingly, oxotremorine-mediated potentiation of stimulated striata
116                       The muscarinic agonist oxotremorine methiodide (oxo-M) stimulated PLC in a dose
117 lation by the muscarinic cholinergic agonist oxotremorine methiodide (oxo-M) was examined in sympathe
118 he NAcc with the muscarinic receptor agonist oxotremorine methiodide (OXO: 0.1, 0.3 or 1 nmol/side),
119 avesical administration of the mAChR agonist oxotremorine methiodide (OxoM) elicited concentration-de
120 er, enhancement and inhibition of current by oxotremorine methiodide mimics modulation observed with
121                          Responses to Oxo-M [oxotremorine methiodide N,N,N,-trimethyl-4-(2-oxo-1-pyrr
122 athway, we found that the muscarinic agonist oxotremorine methiodide not only inhibits currents at po
123                       The muscarinic agonist oxotremorine methiodide produced a dose-dependent reduct
124 ceptive (hot plate test) effects of ethanol, oxotremorine, nicotine, baclofen, clonidine, and the can
125 inic acetylcholine receptor (mAChR) agonist, oxotremorine, or the cholinesterase inhibitor, neostigmi
126 The animals received CHP, 25 mg/kg, p.o., or oxotremorine (OX), 0.2 mg/kg, s.c.
127 usions of the muscarinic cholinergic agonist oxotremorine (OXO) immediately after either context trai
128 ) currents are regulated in a slow manner by oxotremorine (oxo-M) and angiotensin II in rat sympathet
129                       The muscarinic agonist oxotremorine restores the plateau potential in B31/B32 a
130 n-selective muscarinic agonists pilocarpine, oxotremorine, RS-86, S-aceclidine, but not the less acti
131          The nonselective muscarinic agonist oxotremorine showed reduced analgesic potency in M(2) re
132 d that the two CMI compounds, in contrast to oxotremorine, showed >6-fold higher affinity for M(4) th
133 rine-induced desensitization, as assessed by oxotremorine-stimulated [5S]GTPgammaS binding.
134                       Both concentrations of oxotremorine tended to augment basal and AMPH-stimulated
135 icacy, from the low-efficacy pilocarpine and oxotremorine to high-efficacy acetylcholine.
136 , and systemic or striatal administration of oxotremorine to these mice triggers dystonic symptoms.
137                                Untreated and oxotremorine-treated Gnal(+/-) mice provide a model of p
138 lts also provide evidence that untreated and oxotremorine-treated Gnal-haplodeficient mice are powerf
139                                 In contrast, oxotremorine-treated rats had a stronger memory for the
140                The antinociceptive effect of oxotremorine was also potentiated and prolonged.
141 age increase in LD-CBF signal in response to oxotremorine was similar for both groups (SHR, 64%+/-22%
142 owmetry (LD-CBF), in response to intravenous oxotremorine, was measured in one cohort of rats to esti
143                 Using the muscarinic agonist oxotremorine, we revealed a unique concentration-respons

 
Page Top